4.8 Article

Clevudine myopathy in patients with chronic hepatitis B

期刊

JOURNAL OF HEPATOLOGY
卷 51, 期 4, 页码 829-834

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2009.04.019

关键词

Clevudine; Hepatitis B; Adverse effects; Myopathy

资金

  1. National Research Foundation of Korea [전06A1102] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Clevudine (L-FMAU) is a thymidine L-nucleoside analogue that was recently introduced for the treatment of chronic hepatitis B virus infection. Previous studies showed that clevudine has potent and sustained antiviral activity without causing viral resistance. No severe adverse event occurred during clinical trials. We describe two cases of drug-induced myopathy during long-term treatment of chronic hepatitis B with clevudine. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据